Kyntra Bio to Report Third Quarter 2026 Financial Results
Key Highlights
- ➤Kyntra Bio (KYNB) will report Q3 2026 results November 16 after market close
- ➤Kyntra Bio schedules investor conference call and webcast at 5:00 PM Eastern
- ➤Roxadustat is approved across Europe, Japan, China, and other countries
- ➤FG-3246 remains in Phase 2 development for metastatic castration-resistant prostate cancer
SAN FRANCISCO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce third quarter 2026 financial results on Monday, November 16 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
Conference Call and Webcast Presentation Kyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call by phone, please register here, and you will be provided with dial in details. A replay of the webcast will also be available for a limited time on the Events & Presentations page on Kyntra Bio’s website.
Get started
Create a free account to read the full story.